Financial Performance - For the nine-month period ended September 30, 2024, sales increased to 8,278,141 in 2023, representing a growth of approximately 17.3% [1] - Net income for the same period rose to 0.60 per share) from 0.40 per share), marking an increase of about 48.9% [1] - In the third quarter, sales remained stable at 3,057,518 in 2023, while net income increased from 0.14 per share) to 0.19 per share), reflecting a growth of approximately 38.1% [1][4] Sales Breakdown - Sales of cosmetic ingredients surged by 68% in the first nine months of 2024 and increased by 8% in the third quarter, primarily driven by sales to the largest cosmetic distributor [2] - Medical lubricants saw a slight decrease of 2% in the third quarter but increased by 4% for the nine-month period compared to 2023 [2] - Pharmaceutical product sales experienced a decline of 6% in the third quarter and 11% for the nine-month period, attributed to a recovery from a supply disruption affecting Renacidin® [2] Cost and Expenses - Total costs and expenses for the nine-month period were 6,206,375 in 2023, indicating an increase of approximately 6.6% [5] - Cost of sales for the nine months was 4,272,043 in 2023, reflecting an increase of about 6% [4] - Operating expenses rose to 1,580,503, showing an increase of approximately 11.5% [4]
United-Guardian Reports Increased Third Quarter Earnings